Fig. 7
- ID
- ZDB-FIG-250806-30
- Publication
- Tonelotto et al., 2025 - Characterization of a water soluble quininib prodrug that blocks metabolic activity and proliferation of multiple cancer cell lines
- Other Figures
- All Figure Page
- Back to All Figure Page
Water-soluble ace-quininib-HCl (3) significantly reduces viability of OMM2.5 and SUIT2-007. (A) A dose dependent decrease in cell metabolic activity was detected following 96 h of treatment with ace-quininib-HCl (3) solubilized in water. Statistical comparisons were performed between the lowest water-soluble drug concentration (2.5 μM) and both higher concentrations (5, 10, 20 μM) and 0.5 % DMSO, showing significant reductions in viability at higher doses. One-way ANOVA with Dunnett's Test for Multiple Comparisons statistical analysis was performed; error bars represent mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001, (N = 3). (B) IC50 value of ace-quininib-HCl (3) in OMM2.5 cells following a 96 h treatment, as determined by metabolic activity assays. (C) A dose-dependent, significant decrease in SUIT2-007 cell metabolic activity was observed following 96 h treatment with ace-quininib-HCl (3) solubilized in water in comparison to 0.125 % water (control). One-way ANOVA with Dunnett's Test for Multiple Comparisons statistical analysis was performed; error bars represent mean ± SEM, ∗∗∗∗p < 0.0001 (N = 3). (D) IC50 value of ace-quininib-HCl (3) solubilized in water in SUIT2-007 cells following a 96 h treatment, as determined by metabolic activity assays. |